Search company, investor...

Hyperion Therapeutics

Founded Year



Acq - P2P | Acquired

Total Raised




About Hyperion Therapeutics

Hyperion Therapeutics is a privately held specialty therapeutics company focused on the development of therapies that address needs in the areas of gastroenterology and hepatology. In partnership with Ucyclyd Pharma, Hyperion is conducting ongoing research and development of HPN-100 for urea cycle disorders, hepatic encephalopathy, and other forms of hyperammonemia.

Headquarters Location

601 Gateway Boulevard Suite 200

South San Francisco, California, 94080,

United States


Missing: Hyperion Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Hyperion Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Hyperion Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Hyperion Therapeutics is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Hyperion Therapeutics Patents

Hyperion Therapeutics has filed 7 patents.

patents chart

Application Date

Grant Date


Related Topics




Diseases of liver, Hepatology, Inflammations, Esophagus disorders, Syndromes


Application Date


Grant Date



Related Topics

Diseases of liver, Hepatology, Inflammations, Esophagus disorders, Syndromes



Latest Hyperion Therapeutics News

Xenotransplant gene editor eGenesis snags transplant expert as CMO; John Tsai, Susanne Schaffert among the hard cuts made at Novartis

Apr 8, 2022

Eliez­er Katz The wait­list for an or­gan trans­plant in the US ex­ceeds 100,000 peo­ple, but the bio­phar­ma world has long strug­gled to find so­lu­tions for the de­mand. In comes the much-talked-about gene edit­ing field. A Cam­bridge, MA biotech is at­tempt­ing to use CRISPR and oth­er gene edit­ing tools to ad­dress the vi­rol­o­gy and im­munol­o­gy chal­lenges as­so­ci­at­ed with xeno­trans­plan­ta­tion, or tak­ing or­gans and cells from one species and putting them in an­oth­er. Pigs have of­ten been con­sid­ered the most like­ly route; a pa­tient re­ceived a ge­net­i­cal­ly mod­i­fied pig heart trans­plant in Jan­u­ary — the first at­tempt in decades — but trag­i­cal­ly passed two months lat­er . The Boston-area com­pa­ny, eGe­n­e­sis, thinks it can ad­dress the his­tor­i­cal hur­dles in a safe and ef­fec­tive path, but the biotech has yet to test its plans in hu­mans. This week, it got one step clos­er to the clin­ic when it named Eliez­er Katz its chief med­ical of­fi­cer. Katz will lead med­ical op­er­a­tions as the biotech tees up kid­ney and islet cells for the clin­ic, with sol­id or­gan pro­grams — heart, liv­er, lung — in the ear­li­er stages of re­search. The com­pa­ny reeled in $125 mil­lion in Se­ries C funds in March 2021. Crit­i­cal­ly, Katz’s ré­sumé boasts near­ly two decades as a trans­plant sur­geon, in­clud­ing stints as di­rec­tor of ab­dom­i­nal trans­plan­ta­tion at In­te­gris Bap­tist Med­ical Cen­ter and di­rec­tor of liv­er trans­plan­ta­tion at Uni­ver­si­ty of Mass­a­chu­setts Med­ical Cen­ter. Since 2004, he’s climbed the lad­der in bio­phar­ma, start­ing with a VP of med­ical af­fairs post at CTI Clin­i­cal Tri­al and Con­sult­ing Ser­vices in the mid-to-late aughts. He then moved to Pfiz­er in 2010, where he served as se­nior di­rec­tor of trans­plan­ta­tion. While there, he helped plan late-stage tri­als for to­fac­i­tinib, mar­ket­ed as Xel­janz for ul­cer­a­tive col­i­tis, rheuma­toid arthri­tis and pso­ri­at­ic arthri­tis. He al­so played a role in re­quest­ing FDA ap­proval of ra­pamycin, sold as Ra­pa­mune, for the treat­ment of the rare and dead­ly lung dis­ease known as lym­phan­gi­oleiomy­omato­sis. Af­ter a few years at Pfiz­er, he moved over to Med­Im­mune, where he was se­nior di­rec­tor of clin­i­cal de­vel­op­ment. That post led him to serve as VP of clin­i­cal de­vel­op­ment at Viela Bio and then at its ac­quir­er Hori­zon Ther­a­peu­tics. At those com­pa­nies, he led the clin­i­cal de­vel­op­ment of Up­liz­na, which is used by adults to treat neu­romyelitis op­ti­ca spec­trum dis­or­der, a chron­ic dis­or­der in which op­tic nerve and spinal cords are over­run with in­flam­ma­tion. Now at eGe­n­e­sis, Katz said in his job un­veil­ing that he be­lieves his new em­ploy­er “has the po­ten­tial to ad­dress this short­age and rad­i­cal­ly im­prove how we treat or­gan fail­ure.” The com­pa­ny has part­ner­ships with Uni­ver­si­ty of Mi­a­mi to eval­u­ate hu­man com­pat­i­ble islet cells in di­a­betes mod­els, Duke Uni­ver­si­ty School of Med­i­cine to con­duct pre­clin­i­cal re­search of gene-edit­ed kid­neys that have been im­plant­ed in non-hu­man pri­mates and an­oth­er gene-edit­ed kid­ney pro­gram with Mass­a­chu­setts Gen­er­al Hos­pi­tal. — Kyle LaHu­cik Su­sanne Schaf­fert → Some of the most rec­og­niz­able names at No­var­tis didn’t es­cape the chop­ping block as CEO Vas Narasimhan in­sti­tutes a ma­jor re­or­ga­ni­za­tion that could save the Swiss phar­ma more than a bil­lion dol­lars a year. Gone are head of de­vel­op­ment/CMO John Tsai and head of on­col­o­gy Su­sanne Schaf­fert in fa­vor of a blend of cor­po­rate strat­e­gy, R&D port­fo­lio strat­e­gy and busi­ness de­vel­op­ment No­var­tis is call­ing Strat­e­gy & Growth, while pres­i­dent of cus­tomer & tech­nol­o­gy so­lu­tions Robert Wel­tevre­den was al­so shown the door. Lutz Hege­mann, No­var­tis’ pres­i­dent, glob­al health, will be in­ter­im chief strat­e­gy & growth of­fi­cer un­til a per­ma­nent suc­ces­sor is named. Else­where at the drug gi­ant, No­var­tis Phar­ma­ceu­ti­cals pres­i­dent Marie-France Tschudin has been giv­en a dif­fer­ent set of re­spon­si­bil­i­ties as pres­i­dent, in­no­v­a­tive med­i­cines in­ter­na­tion­al and chief com­mer­cial of­fi­cer. Be­gin­ning May 16, ex-Dicer­na med­ical chief Shree­r­am Arad­hye will be pres­i­dent, glob­al drug de­vel­op­ment and CMO. And two oth­er No­var­tis vets have earned new ti­tles: Stef­fen Lang (from glob­al head of No­var­tis tech­ni­cal op­er­a­tions to pres­i­dent, op­er­a­tions) and Vic­tor Bul­to (from head of US phar­ma­ceu­ti­cals to pres­i­dent, in­no­v­a­tive med­i­cines US). John Car­roll has more per­spec­tive on the mas­sive changes. → She­fali She­fali Agar­w­al Agar­w­al has been named pres­i­dent and CEO of DNA Dam­age Re­sponse (DDR) biotech Onx­eo out of Paris, suc­ceed­ing in­ter­im chief Julien Mi­ara from In­vus. Ju­dith Gre­ci­et had led the com­pa­ny for the last decade be­fore Mi­ara bridged the gap in Jan­u­ary. Agar­w­al, the for­mer clin­i­cal lead for Ze­ju­la at Tesaro, was CMO and then chief med­ical and de­vel­op­ment of­fi­cer at Epizyme since 2018. She’s al­so a board mem­ber at Grit­stone bio, Fate Ther­a­peu­tics and ITB Med. Guowei Fang → In keep­ing with Mas­ters week, Leg­end hopes they’ve split the fair­way with Guowei Fang as SVP, glob­al head of re­search and ear­ly de­vel­op­ment fol­low­ing the March 30 res­ig­na­tion of founder and CSO Frank Fan, who stayed long enough to see their J&J-part­nered BC­MA CAR-T cil­ta-cel (now Carvyk­ti) earn ap­proval in late Feb­ru­ary. Fang will try to fill Fan’s shoes af­ter two years as SVP, re­search at Zymeworks and lead­er­ship roles with Ab­b­Vie and Phar­ma­cyclics. John Maraganore → It’s been a mere four weeks since Peer Re­view broke out the Maraganore Me­ter, but we have an­oth­er rea­son to crank it up again as Take­da pro­pos­es John Maraganore’s ap­point­ment to the board of di­rec­tors. In the event of an ap­proval, the ex-Al­ny­lam CEO and Kim­ber­ly Reed — the for­mer pres­i­dent, CEO and chair of the Ex­port-Im­port Bank of the Unit­ed States — will of­fi­cial­ly be­come board mem­bers on June 29, re­plac­ing the re­tir­ing Toshiyu­ki Shi­ga and Shi­ro Ku­niya. We’re not through with Maraganore: He’ll al­so grab a seat on the ad­vi­so­ry board of Treg biotech Aba­ta Ther­a­peu­tics along­side co-founder and chair Di­ane Math­is, Charles Cooney, and Ger­ald Nepom. Mar­go Geor­giadis → Noubar Afeyan has teed up an­oth­er CEO-part­ner in Flag­ship Pi­o­neer­ing’s sta­ble of star­tups, and this time it’s Mar­go Geor­giadis who will lead a com­pa­ny still in stealth mode. Geor­giadis, a board mem­ber at Mc­Don­ald’s since 2015, has had some irons in the fire af­ter her de­par­ture as CEO of An­ces­ in 2021, serv­ing as en­durance part­ner-in-res­i­dence at Gen­er­al Cat­a­lyst and man­ag­ing part­ner at Synetro Group. She fol­lows in the foot­steps of oth­er CEO-part­ners at Flag­ship such as Fab­rice Chouraqui (CEO of Cel­lar­i­ty), Diego Mi­ralles (CEO of Laronde) and for­mer FDA com­mis­sion­er Stephen Hahn (CEO of Har­bin­ger Health). → One big hap­py re­union is com­ing right up over at Ver­tex, as Doug Melton is gear­ing up to join next month on May 2 as the com­pa­ny’s first “Dis­tin­guished Ver­tex Fel­low.” The move from his cur­rent job at Har­vard al­lows Melton to get to­geth­er with his for­mer Sem­ma col­lab­o­ra­tors: Ver­tex chief of cell & gene ther­a­pies Bas­tiano San­na (for­mer­ly Sem­ma’s CEO), Ver­tex CSO David Alt­shuler (who first met Melton in Grad school and has kept in touch since), and Ver­tex dis­ease area ex­ec­u­tive for type I di­a­betes Fe­li­cia Pagli­u­ca (Sem­ma co-founder). Melton’s new role will have him run­ning a re­search group in or­der to de­vel­op “cu­ra­tive cell ther­a­pies.” Robert Siko­rs­ki → Pre­mal Pa­tel has re­signed as CMO of eF­FEC­TOR Ther­a­peu­tics to take the CEO job at Cellinfin­i­ty Bio, and while the search is on for his suc­ces­sor, ex-Five Prime CMO Robert Siko­rs­ki will take on a greater role as se­nior clin­i­cal de­vel­op­ment ad­vi­sor. San Diego-based eF­FEC­TOR an­nounced in Jan­u­ary that they were more or less start­ing from scratch by “halt­ing the de­vel­op­ment of tomivosert­ib in non-small cell lung can­cer pa­tients who have al­ready pro­gressed on Keytru­da monother­a­py,” as our Am­ber Tong re­port­ed at the time. But the Phase Ib KICK­START tri­al now fea­tures a new co­hort for “vir­tu­al­ly all PD-L1 pos­i­tive pa­tients,” eF­FEC­TOR CEO Steve Wor­land said. Michael Krams → Us­ing AI to blaze trails in drug dis­cov­ery, Ex­sci­en­tia kept the cash flow­ing and stacked up more part­ner­ships in the last year, go­ing pub­lic with an IPO that end­ed up ex­ceed­ing a half bil­lion dol­lars. This week CEO An­drew Hop­kins has poached Michael Krams from J&J’s Janssen to be chief quan­ti­ta­tive med­i­cine of­fi­cer. Krams, Janssen’s glob­al head of quan­ti­ta­tive sci­ences since 2013, left Wyeth to lead J&J’s neu­rol­o­gy fran­chise in 2010. Among the lat­est al­liances, Sanofi paid $100 mil­lion up­front in a Jan­u­ary AI deal with Ex­sci­en­tia that could yield as many as 15 drugs. Sef Kurst­jens → Sum­i­to­vant’s urol­o­gy sub Urovant has called up Sef Kurst­jens from the board of di­rec­tors to be CMO, re­plac­ing Cor­nelia Haag-Molken­teller. A board mem­ber since the sum­mer of 2018, Kurst­jens — the for­mer CMO at Al­ler­gan and Astel­las — was CEO at Bright Peak Ther­a­peu­tics from 2019-21. Urovant is look­ing to tack on an­oth­er in­di­ca­tion with its over­ac­tive blad­der drug Gemte­sa, ap­proved in late 2020, for men with be­nign pro­sta­t­ic hy­per­pla­sia. Fran­cois Lilien­thal → MindMed CEO Robert Bar­row par­tic­i­pat­ed in our psy­che­delics we­bi­nar last week with Nicole De­Feud­is, and now the com­pa­ny fo­cused on brain health dis­or­ders has se­lect­ed Fran­cois Lilien­thal as chief com­mer­cial of­fi­cer. Lilien­thal had a se­ries of roles at Bris­tol My­ers Squibb, Janssen and Ti­botec, then held mul­ti­ple ex­ec­u­tive po­si­tions at Mer­ck from 2007-21, spear­head­ing the launch­es of HIV in­te­grase in­hibitor Isen­tress and he­pati­tis C drug Zepati­er. In Jan­u­ary, the FDA lift­ed the clin­i­cal hold placed on MindMed a month ear­li­er for its gen­er­al­ized anx­i­ety dis­or­der can­di­date MM-120. Shamik Parikh → Kath­leen Se­be­lius-chaired Hu­ma­cyte, which caught a SPAC wave last year by merg­ing with Ra­jiv Shuk­la’s Al­pha Health­care Ac­qui­si­tion Corp. to the tune of $255 mil­lion, has ap­point­ed Shamik Parikh as CMO. Parikh joins CEO Lau­ra Nikla­son’s hu­man acel­lu­lar ves­sel de­vel­op­er af­ter a 17-year run at As­traZeneca, where he be­came glob­al clin­i­cal lead for Farx­i­ga and lat­er the phar­ma gi­ant’s head of Pa­tient Safe­ty Cen­ter of Ex­cel­lence. Adri­an Ray → Led by for­mer Au­dentes CEO Na­tal­ie Holles and nab­bing a $105 mil­lion Se­ries B in Feb­ru­ary to tar­get chron­ic ur­ticaria, Third Har­mon­ic Bio has tapped Adri­an Ray as CSO. Now run­ning the de­vel­op­ment of THB001, Ray is a 16-year Gilead vet who was head of trans­la­tion­al sci­ences at Mor­phic Ther­a­peu­tic and lat­er the Waltham, MA biotech’s SVP of bi­ol­o­gy and trans­la­tion. → While we’re on the sub­ject of Mor­phic Ther­a­peu­tic, pres­i­dent and CEO Praveen Tipir­neni has plugged in one new ex­ec and pro­mot­ed an­oth­er: Shire and Take­da alum Bri­had Ab­hyankar, Mor­phic’s VP of clin­i­cal de­vel­op­ment, is the for­mer head of clin­i­cal de­vel­op­ment at Akari Ther­a­peu­tics who was ex­ec­u­tive med­ical di­rec­tor and pro­gram team leader at Ther­a­vance Bio­phar­ma. Mean­while, Mor­phic has bumped up Aaron Pelta to SVP, busi­ness and cor­po­rate de­vel­op­ment. Pelta, a Cu­bist Phar­ma­ceu­ti­cals vet, be­gan his time at Mor­phic in 2019 af­ter al­most three years at Ar­sa­nis, where he was VP, busi­ness de­vel­op­ment and com­mer­cial­iza­tion. Mor­phic’s col­lab­o­ra­tion with Am­gen got trimmed in Feb­ru­ary when they shut down re­search in­to the αVβ6 in­te­grin. Chris Car­pen­ter → VC firm Sofinno­va has plugged in Chris Car­pen­ter as an ex­ec­u­tive part­ner. The Cata­ma­ran Bio CMO has al­so been med­ical chief at Ru­bius, and at GSK, Car­pen­ter was SVP and head of the can­cer epi­ge­net­ics group. Wil­son Che­ung → Now un­der the in­ter­im lead­er­ship of chief tech­nol­o­gy of­fi­cer John Ng and de­liv­er­ing promis­ing re­sults at ASH in De­cem­ber with TT11 and TT11x, Sin­ga­pore cell ther­a­py biotech Tes­sa Ther­a­peu­tics has picked up Wil­son Che­ung as CFO. For the last three years, Che­ung was fi­nance chief at can­cer-fo­cused Apol­lomics, guid­ing the com­pa­ny to its $124 mil­lion Se­ries C fi­nanc­ing. He’s al­so been CFO for KBP Bio­sciences and Sci­Clone Phar­ma­ceu­ti­cals. Rich Kol­len­der → Rich Kol­len­der has been named CFO and CBO at Re­ac­tion Bi­ol­o­gy, where John John­son just took charge as CEO a few weeks ago. Pri­or to join­ing Re­ac­tion, Kol­len­der served as pres­i­dent and CFO at John­son’s pre­vi­ous stop, Strong­bridge Bio­phar­ma, which was ac­quired by Xeris Bio­phar­ma in Oc­to­ber 2021. He has al­so worked in sales, mar­ket­ing, and world­wide busi­ness de­vel­op­ment at GSK. → Chris Min has tak­en over as CMO at cell ther­a­py biotech Longeveron. Most re­cent­ly, Min served as VP and head of med­ical & clin­i­cal de­vel­op­ment at En­terin and has al­so served as head of clin­i­cal phar­ma­col­o­gy at Cerev­el Ther­a­peu­tics. Min be­gan his ca­reer in in­dus­try at Mer­ck. Todd Dru­ley → Near­ly a year to the day af­ter Yan Zhang suc­ceed­ed Char­lie Sil­ver as CEO, Mis­sion Bio has hired a CMO fa­mil­iar with its sin­gle-cell se­quenc­ing plat­form, named Ta­pes­tri. Todd Dru­ley, a mem­ber of Wash­ing­ton Uni­ver­si­ty School of Med­i­cine’s fac­ul­ty from 2010-21, has al­so been med­ical chief with AN­GLE Bio­sciences and ArcherDX. “I’ve worked with the Ta­pes­tri Plat­form since 2016 when test­ing the pro­to­type on pe­di­atric AML MRD sam­ples in my re­search lab­o­ra­to­ry, so I’ve al­ways been a huge fan, and am ec­sta­t­ic to join the Mis­sion Bio team,” Dru­ley said in a state­ment . Jane Huang → With Je­cure Ther­a­peu­tics vets at the con­trols , a Ver­sant-led $60 mil­lion Se­ries A and a name in­spired by a San Diego area code, 858 Ther­a­peu­tics has pro­mot­ed Gretchen Bain to SVP of bi­ol­o­gy and brought in San­jay Tre­han as SVP of busi­ness de­vel­op­ment. Bain, the VP of bi­ol­o­gy since the start­up’s of­fi­cial launch in Sep­tem­ber 2021, held the same post at Je­cure and has pre­vi­ous­ly been ex­ec­u­tive di­rec­tor of bi­ol­o­gy at Ami­ra Phar­ma­ceu­ti­cals. A Sanofi alum, Tre­han spent the last two years as busi­ness de­vel­op­ment project leader at Genen­tech, which bought Je­cure in 2018. An­oth­er im­por­tant 858 note: Jane Huang, the new pres­i­dent and CMO at Pre­lude Ther­a­peu­tics and the ex-CMO of hema­tol­ogy with BeiGene, has been elect­ed to the board of di­rec­tors. → UK vac­cine out­fit ios­Bio has re­cruit­ed Ben War­riner as CFO. War­riner hails from Free­line Ther­a­peu­tics, where he was VP of fi­nance, and in be­tween sep­a­rate stints at EU­SA Phar­ma, he worked at Jazz Phar­ma­ceu­ti­cals as head of fi­nance, in­ter­na­tion­al. Kathy Scott → ARS Phar­ma­ceu­ti­cals — the de­vel­op­er of the ep­i­neph­rine nasal spray Neffy that bagged a $55 mil­lion Se­ries C last sum­mer — has wel­comed Er­ic Karas as chief com­mer­cial of­fi­cer and Kathy Scott as CFO. Karas piv­ots to ARS from Emer­gent BioSo­lu­tions, where he was VP & gen­er­al man­ag­er of com­mer­cial, North Amer­i­ca. Scott has am­ple ex­pe­ri­ence in this par­tic­u­lar are­na, tak­ing on the role of fi­nance chief at nu­mer­ous com­pa­nies like Onc­ter­nal Ther­a­peu­tics, Re­cros Med­ica and most re­cent­ly, Neu­rana Phar­ma­ceu­ti­cals. There’s an RA Cap­i­tal con­nec­tion with Scott as a for­mer part­ner and Pe­ter Kolchin­sky on ARS’ board, which al­so in­cludes ex-Al­ler­gan boss Brent Saun­ders. → CAR-T-fo­cused In­no­v­a­tive Cel­lu­lar Ther­a­peu­tics is bring­ing in a new duo to its lead­er­ship team with the ap­point­ments of Lucy Lu as COO and Robert Dal­limore as SVP of qual­i­ty & com­pli­ance. Lu hops aboard af­ter run­ning the helm as CEO and pres­i­dent of Av­enue Ther­a­peu­tics. Pre­vi­ous­ly she served as CFO and EVP of Fortress Biotech. Mean­while, Dal­limore joins the Rockville, MD-based com­pa­ny af­ter a stint as VP of qual­i­ty at Macro­Gen­ics. Be­fore that, Dal­limore had gigs at Te­va Phar­ma­ceu­ti­cals (di­rec­tor of qual­i­ty), In­ter­cell USA (VP of qual­i­ty), Med­Im­mune, Av­i­ron and Evans Vac­cines. → Paris-based Bio­phytis is rop­ing in Philippe Rousseau as CFO, suc­ceed­ing Eve­lyne Nguyen “who is leav­ing to pur­sue oth­er projects.” Rousseau brings to the ta­ble ex­pe­ri­ence from his time as COO of Pher­recy­des Phar­ma; deputy CEO of ABCDx and CFO of Therabron Ther­a­peu­tics. → OcuTer­ra, a new oph­thalmic dis­ease biotech chaired by Saun­ders that chalked up $35 mil­lion in a Se­ries B round last fall, has in­stalled Ma­jid An­dere­si as VP of clin­i­cal and med­ical af­fairs. An­dere­si’s one year as se­nior med­ical di­rec­tor of TA oph­thal­mol­o­gy at Al­ler­gan over­lapped on­ly slight­ly with Saun­ders’ reign as CEO, and from there he was group clin­i­cal di­rec­tor of oph­thal­mol­o­gy at Roche and re­cent­ly the glob­al med­ical af­fairs di­rec­tor for the oph­thal­mol­o­gy fran­chise at No­var­tis. Deepi­ka Ra­jesh → Van­cou­ver in­duced pluripo­tent stem cell (iP­SC) play­er Notch Ther­a­peu­tics has bol­stered its team with Deepi­ka Ra­jesh as VP, stem cell bi­ol­o­gy & de­vel­op­men­tal im­munol­o­gy. Ra­jesh has an ex­ten­sive iP­SC back­ground from Fu­ji­film Cel­lu­lar Dy­nam­ics, where she was se­nior di­rec­tor, R&D and be­gan as a se­nior sci­en­tist in 2008. Michelle Mel­lion → Peren­ni­al Peer Re­view oc­cu­pant Pep­Gen has been liv­ing rent-free here late­ly — af­ter a pair of ex­ecs joined the com­pa­ny last week, Michelle Mel­lion has signed on as SVP, head of clin­i­cal de­vel­op­ment. Mel­lion steps away from Ful­crum Ther­a­peu­tics, where she had been head of neu­ro­mus­cu­lar clin­i­cal de­vel­op­ment. Be­fore join­ing Ful­crum in 2018, she was as­so­ciate med­ical di­rec­tor with Bio­gen and med­ical di­rec­tor at Ver­tex. → Aussie-based Mi­cro­ba Life Sci­ences is tack­ing on Trent Munro as SVP of ther­a­peu­tics. Munro is a pro­fes­sor and se­nior group leader at the Aus­tralian In­sti­tute for bio­engi­neer­ing and nan­otech­nol­o­gy at the Uni­ver­si­ty of Queens­land and pre­vi­ous­ly held a 6-year stint as ex­ec­u­tive di­rec­tor of Am­gen. Vic­tor Lobanov → Vic­tor Lobanov is now on board as head of com­pu­ta­tion­al sci­ences at Ven­tus Ther­a­peu­tics, the biotech backed by RA Cap­i­tal and Soft­Bank that just named Chris­tine Ha as CFO last week. A long­time J&J vet who was di­rec­tor of the Big Phar­ma’s In­for­mat­ics Cen­ter of Ex­cel­lence, Lobanov has al­so served as VP, in­for­mat­ics so­lu­tion de­vel­op­ment for Co­v­ance. → Tes Igna­cio has got­ten the call to be VP, med­ical af­fairs for Is­raeli pres­by­opia biotech Ora­sis Phar­ma­ceu­ti­cals, which is in two Phase III tri­als for its cor­rec­tive eye drop CSF-1. Ear­li­er, Igna­cio was ex­ec­u­tive med­ical di­rec­tor (dry eye/cornea/re­frac­tive) at Al­ler­gan. Su­san Franks → Seat­tle-UK start­up Eliem Ther­a­peu­tics has ush­ered in Su­san Franks as SVP and head of reg­u­la­to­ry af­fairs. Franks makes her way to chron­ic pain and CNS-fo­cused Eliem from Brae­burn, a com­pa­ny cen­tered on opi­oid use dis­or­der, where she held the same ti­tle. Her time at Te­va Phar­ma­ceu­ti­cals con­clud­ed as VP, glob­al reg­u­la­to­ry af­fairs in 2017. Eliem hit a Nas­daq scene that was teem­ing with new en­tries in the sum­mer of 2021, not even two months af­ter a $60 mil­lion Se­ries B round . → Greg Duczyn­s­ki is leav­ing Pfiz­er be­hind af­ter 32 years and start­ing a new chap­ter as SVP for clin­i­cal op­er­a­tions at Los An­ge­les-based Enochi­an Bio­Sciences, a de­vel­op­er of cell ther­a­pies for HIV and can­cer. Duczyn­s­ki had spent the last six years as Pfiz­er’s se­nior di­rec­tor, clin­i­cal de­vel­op­ment and op­er­a­tions and clin­i­cal study team leader. → Some big stars are mak­ing their way on­to the board of di­rec­tors of Fred Hutch-backed Affi­ni-T Ther­a­peu­tics. Michael Var­ney, who most re­cent­ly served as Genen­tech’s EVP and head of re­search and ear­ly de­vel­op­ment, and for­mer Mi­rati COO Daniel Fa­ga are com­ing along for the ride as the com­pa­ny takes their fresh in­fu­sion of $175 mil­lion on its quest to dive deep­er in­to KRAS. Var­ney cur­rent­ly serves as chair of R&D, SAB mem­ber and board di­rec­tor of Eras­ca and for­mer­ly had a gig on Roche’s cor­po­rate ex­ec­u­tive com­mit­tee. On the oth­er hand, Fa­ga pre­vi­ous­ly served as CBO of Spark and cur­rent­ly serves as in­ter­im CEO of Anap­tys­Bio. Saurabh Sa­ha → Centes­sa CEO Saurabh Sa­ha has clinched a board seat at on­col­o­gy-fo­cused Scor­pi­on Ther­a­peu­tics, helmed by first-year CEO and GSK vet Ax­el Hoos. Be­fore lead­ing Centes­sa, Sa­ha was SVP of R&D at Bris­tol My­ers. → Per­cep­tive’s Chi­na start­up Lian­Bio, which jumped on­to Nas­daq on the strength of a $325 IPO last fall, has giv­en a seat to Wei Wei Chen on the board of di­rec­tors. Chen, the for­mer CFO, Asia of Sanofi, left bio­phar­ma to be­come CFO of the Chi­na di­vi­sion at Yum! and, most re­cent­ly, the VP and CFO for Star­bucks (Chi­na). Tonya Williams → Jose-Car­los Gutiér­rez-Ramos and Tonya Williams are the newest mem­bers of the board at in­flam­ma­to­ry dis­ease biotech Evelo Bio­sciences that’s chaired by Flag­ship’s David Ep­stein. Gutiér­rez-Ramos briefly led glob­al drug dis­cov­ery at Ab­b­Vie be­fore be­com­ing the CSO of Dana­her, while Williams is head of ex­ter­nal af­fairs and cor­po­rate re­spon­si­bil­i­ty for Soft­Bank Group In­ter­na­tion­al. → From one David Ep­stein to an­oth­er — Black Di­a­mond has made room for Wendy Dixon on the board of di­rec­tors, while Ver­sant chair­man and man­ag­ing part­ner Brad Bol­zon re­signs af­ter five years as a board mem­ber. Dixon, Bris­tol My­ers’ chief mar­ket­ing of­fi­cer and pres­i­dent, glob­al mar­ket­ing from 2001-09, holds board ap­point­ments at Alk­er­mes, In­cyte and Arv­inas. Karen Akin­sanya → Seat­tle pro­teomics play­er Nau­tilus Biotech­nol­o­gy has elect­ed Karen Akin­sanya to the board of di­rec­tors. Akin­sanya, the pres­i­dent of R&D, ther­a­peu­tics at Schrödinger and a 2019 Women in Bio­phar­ma R&D hon­oree , spent near­ly 12 years at Mer­ck and is on the sci­en­tif­ic ad­vi­so­ry board at Vari­ant Bio and Ther­mo Fish­er. → Rus­sell Greig has been named chair­man of the board at Ger­man biotech Car­dior, which is us­ing non-cod­ing RNA (ncR­NA) to de­vel­op ther­a­pies for heart dis­ease. He suc­ceeds Markus Hosang, who will slide in­to the role of vice chair­man. Greig was pres­i­dent of SR One dur­ing a lengthy tenure at GSK that be­gan in 1980. → CAR-NK cell ther­a­py de­vel­op­er Cata­ma­ran Bio, which emerged from stealth back in 2020, has brought out a seat for Frank Lee as chair­man of its board of di­rec­tors. Lee is the CEO of For­ma Ther­a­peu­tics and pre­vi­ous­ly served as SVP, glob­al prod­uct strat­e­gy, and ther­a­peu­tic area head for the im­munol­o­gy, oph­thal­mol­o­gy and in­fec­tious dis­eases at Genen­tech. Not on­ly that, but Lee has been run­ning stints at No­var­tis, Janssen and Eli Lil­ly. Cather­ine Mack­ey → Af­ter bring­ing on for­mer Onyx Phar­ma­ceu­ti­cals founder and CSO Frank Mc­Cormick as chair for its sci­en­tif­ic ad­vi­so­ry board back in Jan­u­ary, syn­thet­ic lethal­i­ty play­er Ideaya Bio­sciences has ap­point­ed Cather­ine Mack­ey to its board of di­rec­tors. Mack­ey for­mer­ly served as SVP of Pfiz­er world­wide R&D and as di­rec­tor of Pfiz­er’s La Jol­la Lab­o­ra­to­ries. → For­mer Al­ge­ta pres­i­dent and CEO Thomas Ram­dahl has been nom­i­nat­ed to join the board of di­rec­tors at Nordic Nanovec­tor, now un­der the di­rec­tion of CEO Erik Skullerud. Ram­dahl joined Al­ge­ta in 2001 and saw the com­pa­ny through its sale to Bay­er in 2014. Ram­dahl is cur­rent­ly chair­man at Pre­crir­ix and a board di­rec­tor at Clar­i­ty Phar­ma­ceu­ti­cals, both ra­dio­phar­ma out­fits. → South San Fran­cis­co-based Ap­plied Mol­e­c­u­lar Trans­port has added Char­lene Ba­nard, the fresh­ly-mint­ed chief tech­nol­o­gy of­fi­cer at Atara Bio­ther­a­peu­tics, to the board of di­rec­tors. Ba­nard had pre­vi­ous­ly been glob­al head, tech­ni­cal op­er­a­tions, cell & gene ther­a­py plat­form for No­var­tis. → Mar­tin Mack­ay’s Rally­bio is bring­ing in some fresh faces to its board of di­rec­tors with the ap­point­ments of Chris­tine Nash and Hui Liu. Nash cur­rent­ly serves as board chair and se­nior ad­vi­sor to the pres­i­dent and CEO at The CM Group. Pri­or to that, Nash was CCO at Hy­pe­r­i­on Ther­a­peu­tics and held roles at Cother­ix and Gene­soft Phar­ma­ceu­ti­cals. Mean­while, Liu cur­rent­ly serves as EVP, CBO and head of US at Merus. Pri­or to his cur­rent job, Liu was glob­al head of busi­ness de­vel­op­ment & li­cens­ing at No­var­tis On­col­o­gy. Oth­er stints in­clud­ed roles at No­var­tis Vac­cines & Di­ag­nos­tics and Pfiz­er. Derek Graf al­so con­tributed to this edi­tion. AUTHORS John Carroll Editor & Founder Right on the heels of back-to-back breakthrough therapy designations for its lead RSV vaccine, Pfizer is wagering up to $525 million on a biotech buyout that injects new RSV assets into its pipeline. Pfizer is snapping up ReViral after inspecting mid-stage data for sisunatovir, an oral drug that blocks the fusion of RSV with host cells. And there’s more. In their statement, Pfizer noted: Sisunatovir significantly reduced viral load in a phase 2 RSV human challenge study in healthy adults and is currently in Phase 2 clinical development in infants. The development program for sisunatovir is expected to continue in both adult and pediatric populations. A second program is focused on the inhibition of RSV replication targeting the viral N protein. The lead candidate in this program is currently in Phase 1 clinical development. Keep reading Endpoints with a free subscription Unlock this story instantly and join 138,400+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Zachary Brennan Senior Editor As Congress grapples with how to reform and lower prescription drug costs and may have to settle for a $35 monthly insulin cap, new research points to the concerning extent to which seniors skip out on their medicines because of high prices. Under the Medicare Part D standard benefit, beneficiaries who do not receive a low-income subsidy must pay a percentage of a drug’s list price with every prescription fill. For those who are on expensive or “specialty” drugs, these high up-front costs may result in seniors never starting a new drug, which was the case in four different treatment areas that the researchers, led by Vanderbilt’s Stacie Dusetzina and Harvard’s Haiden Huskamp, wrote about in Health Affairs . Keep reading Endpoints with a free subscription Unlock this story instantly and join 138,400+ biopharma pros reading Endpoints daily — and it's free. SIGN UP The wait is almost over. The Centers for Medicare and Medicaid Services sometime in the next few days will finally offer its ultimate decision on whether to pay for Biogen’s controversial Alzheimer’s drug and others that might target the sticky plaques known as amyloids — a costly expenditure to be sure — even as the drugs have so far failed to establish a clinical benefit. Some background: In January, several months after Biogen’s R&D chief Al Sandrock jumped ship , and not for retirement , CMS released its draft decision saying that, starting in 90 days, it will only pay for Biogen’s Aduhelm and other FDA-approved anti-amyloid monoclonal antibodies for Alzheimer’s disease under CMS-approved randomized controlled trials. Keep reading Endpoints with a free subscription Unlock this story instantly and join 138,400+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Max Gelman Editor A bruising bear market has left the biotech sector bereft of IPOs in recent months, but in a small sign of market activity, two companies filed to go public over the last two days. On Wednesday, HilleVax, a norovirus vaccine developer spunout from Takeda by late biotech legend Tachi Yamada, submitted its SEC paperwork, penciling in an initial $100 million estimate. The filing came a day after Belite Bio submitted its own F-1 — a registration statement for foreign companies — seeking $46 million in its estimate. Keep reading Endpoints with a free subscription Unlock this story instantly and join 138,400+ biopharma pros reading Endpoints daily — and it's free. SIGN UP LOG IN

Hyperion Therapeutics Frequently Asked Questions (FAQ)

  • When was Hyperion Therapeutics founded?

    Hyperion Therapeutics was founded in 2006.

  • Where is Hyperion Therapeutics's headquarters?

    Hyperion Therapeutics's headquarters is located at 601 Gateway Boulevard, South San Francisco.

  • What is Hyperion Therapeutics's latest funding round?

    Hyperion Therapeutics's latest funding round is Acq - P2P.

  • How much did Hyperion Therapeutics raise?

    Hyperion Therapeutics raised a total of $156.61M.

  • Who are the investors of Hyperion Therapeutics?

    Investors of Hyperion Therapeutics include Horizon Therapeutics, New Enterprise Associates, Highland Capital Partners, Sofinnova Ventures, Bay City Capital and 6 more.

  • Who are Hyperion Therapeutics's competitors?

    Competitors of Hyperion Therapeutics include Radius, Annovis Bio, Aegerion Pharmaceuticals, CoImmune, BioCardia and 11 more.

Compare Hyperion Therapeutics to Competitors


Altheos, Inc. is an early-stage biopharmaceutical company focused on the identification and development of promising well-differentiated novel small molecule drugs for unmet medical needs. Altheos, Inc. was co-founded in 2009 by two experienced pharmaceutical drug development executives and entrepreneurs, Henry H. Hsu, M.D. and M. (Ken) Kengatharan, Ph.D. The company is headquartered in South San Francisco, California.

Epiphany Biosciences

Epiphany Biosciences is focused on advancing new therapies for infectious disease. The founders include Fred Volinsky MD, Robert Gallo MD, David Myles Ph.D and Barry Selick Ph.D. Epiphany is located in San Francisco, California.

Opal Therapeutics

Opal Therapeutics is an immunotherapy company focused on therapies for human immunodeficiency virus (HIV) and Hepatitis C (HCV), based on technology from the University of Melbourne.

Synapsin Pharmaceuticals

SYNAPSIN is developing therapeutic strategies for the treatmentand prevention ofneurodegenerative disorders such as Alzheimer's disease (AD),Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and spinal cord injury.


The company are developing siRNA drugs targeting a control factor for HIF (hypoxia-inducible factor), which is one of the main factors involved in angiogenesis. The company have found that siRNA can promote angiogenesis by inducing expression of several angiogenic factors simultaneously by preventing breakdown of HIF inside the cell. It is therefore expected that delivery of siRNA to disease-affected sites can efficiently induce angiogenesis, leading to a in treatment for obstructive arteriosclerosis.

NeoCytex BioPharma

NeoCytex BioPharmaceuticals develops therapeutics to promote the repair and rejuvenation of damaged tissues. The lead drug candidate NBI-18 is being developed for speeding up recovery from neurodegenerative (Parkinson's, Alzheimer's) and cerebrovascular diseases.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.